Have a personal or library account? Click to login
Hypercapnia outcome in COVID-19 acute respiratory distress syndrome patients on mechanical ventilator: A retrospective observational cohort Cover

Hypercapnia outcome in COVID-19 acute respiratory distress syndrome patients on mechanical ventilator: A retrospective observational cohort

Open Access
|Jan 2025

Figures & Tables

Fig. 1.

Study Profile
Study Profile

Fig. 2.

ROC curve for weighted regression
ROC curve for weighted regression

Multivariable Analysis (ROC=0_88)

OR95% CIp-value
Severe hypercapnia1.080.28–3.480,993
SAPS II1.13471.05–1.220.001
Prone positioning0.45740.15–1.380.165
Hospital-acquired infections1.40120.52–3.750.503
Hemodynamic instability7.23082.49–20.90.000
Dead space1.27781.01–1.600.033
Minute ventilation1.33990.94–1.890.100
Plateau Pressure0.91000.76–1.070.272
Predicted body weight0.91820.85–0.980.012
PaO2/FiO2 ratio0.99220.98–1.000.125
Charlson Comorbidity Index0.84130.53–1.310.451

Clinical characteristics of patients with severe hypercapnia and no severe hypercapnia

No severe hypercapnia (n=151)Severe hypercapnia (n=137)p-value
Age (years)60 [50.5–69.0]61 [53, 65]0.90
Male sex (n (%))85 (56)84(61)0.45
Predicted body weight (kg)67 [62–72]64 [58–70]0.01
Charlson comorbidity index (points)2 [1–3]2 [2–3]0.99
Simplified Acute Physiology Score II (points)38 [32–42]38 [33–42]0.97

Co-morbid
Hypertension (n (%))86 (57.0)87 (63.5)0.31
Asthma (n (%))9 (6.05 (3.6)0.52
Chronic obstructive lung disease (n (%))4 (2.6)7 (5.1)0.43
Restrictive lung disease (n (%))1(0.7)01.00
Diabetes mellitus (n (%))75 (49.7)66 (48.2)0.89

Treatment during ICU stay
Prone positioning (n (%))65(43)8(58.4)0.01
Remdesivir (n (%))114(75)108 (78)0.59
Tocilizumab (n (%))50(33)56(40)0.21
Neuromuscular block (n (%))138 (93.9)137 (97.2)0.28
Steroid (n (%))141 (95.9)138 (97.9)0.53
NIV use (n (%))117(77)125(91)0.002
Recruitment (n (%))11 (7.3)11 (8)0.98

Arterial blood gases (a day before intubation)
pH7.3 (7.3–7.4)7.4 (7.3_7.4)0.01
PaCO2 (mmHg)36 [31–41]39.9 [35–48]0.0001
PaO2 (mmHg)69.1 [56.1–88.0]63.5 [55–76]0.03
PaO2/FiO2 (ratio)79 [63–124]70 [57–86]0.000
Lactate1.8(1.2–2.5)2(1.2–1.4)0.73

Arterial blood gases (after 24 hours of mechanical ventilation)
pH7.3(7.3_7.4)7.3(7.2–7.4)0.00
PaCO2 (mmHg)40(35–45)54(48–60)0.00
PaO2 (mmHg)80.2 [68.9, 103]73 [65, 86.2]0.002
Lactate1.8(1.2–2.5)2(1.3–2.2)0.98
PaO2/FiO2 (ratio)122[ 88–182]93[ 73–123]0.001
Tidal volume(ml/kg)6.1(5.9–6.5)6(5.8–5.6)0.08
Tidal volume(ml)400 [400, 440]400 [350, 420]0.000
Set respiratory rate28 [25–30]30 [28–35]0.0001
Minute ventilation11.2 [ 9.6–12.6]12 [10–12]0.07
Applied peep10.5 (8–12)10 (8–10)0.45
Plateau pressure29 [28, 30]30 [28, 30]0.003
Driving pressure18 [16, 20]19 [16, 21]0.03
Static compliance22 [18–27]23 [19, 25.0]0.41
Corrected minute ventilation11 [ 9.2, 13.4]16[13, 18.3]0.00
MAP92(85–100)92(85–102)0.63
Heart rate100(90–110)101(90–114)0.10

Mortality127(84)130(94)0.04

Univariate Regression Analysis

OR (95%CI)p-value
Severe hypercapnia3.5096 (1.4605, 8.4333)0.005
Age1.05 (1.02, 1.09)0.003
Gender, male0.84 (0.40, 1.80)0.6
Predicted body weight0.96 (0.92, 1.01)0.11
SAPSII1.11 (1.06, 1.17)<0.001
Charlson Comorbidity Index1.14 (1.06, 1.91)0.022
Non-invasive ventilation before intubation2.29 (0.94, 5.20)0.056
Prone positioning0.50 (0.22, 1.07)0.082
Use of steroid7.47 (1.76, 29.9)0.004
Use of Tociluzumab0.79 (0.37, 1.71)0.5
Use of Remdisivir0.79 (0.28, 1.90)0.6
Use of neuromuscular block8.57 (2.58, 27.8)<0.001
PaO2/FiO2 ratio before mechanical ventilation1.00 (0.99, 1.00)0.2

After 24-h of ventilation
PaO2/FiO2 ratio0.99 (0.99, 1.00)0.009
Tidal volume, ml1.00 (0.99, 1.00)0.3
Tidal volume, ml/kg1.18 (0.70, 2.10)0.5
Minute ventilation1.19 (1.01, 1.41)0.042
Respiratory rate1.09 (1.02, 1.17)0.011
Driving pressure0.94 (0.86, 1.03)0.2
Compliance1.02 (0.96, 1.08)0.6
Plateau pressure1.01 (0.90, 1.14)0.8
Dead space1.25 (1.12, 1.41)<0.001
Applied peep1.13 (1.00, 1.29)0.054
Duration of hospital stay0.94 (0.91, 0.98)<0.001
Duration of mechanical ventilation1.02 (0.94, 1.11)0.7
Acidosis2.25 (1.06, 4.88)0.036
Hospital-acquired infections1.93 (0.88, 4.12)0.092
Hemodynamic instability6.36 (2.87, 14.2)<0.001

Secondary outcome in severe hypercapnia and no severe hypercapnia

Severe hypercapniaNo severe hypercapniap-value
Hemodynamic instability125(82)115(83)0.91
Arrhythmia31 (21)25 (17.7)0.79
Acute coronary syndrome40 (27.2)32 (22.7)0.63
Impair liver enzyme11 (7.2)8 (5.0)0.79
Emphysema15 (9)23 (16.3)0.22
Renal replacement therapy48(31)29(28)0.05
Pneumothorax8 (5)11 (8)0.48
Deep vein thrombosis2 (1.3)1 (1.4)1.00
Hospital Acquired Infection99 (65)107 (75.9)0.03
Pulmonary embolism3(2)5 (2)0.13
Ventilator duration7 [ 4, 10]6 [ 4, 10]0.19
Hospital length of stay11 [ 8, 15]14 [ 9, 21]0.04
Ventilator duration in survivals(days)11(6–21)6.3(4.5–5.75)0.065
Hospital length of stay in survivals(days)34(29–33)17(14–11)0.005
DOI: https://doi.org/10.2478/jccm-2025-0004 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 44 - 53
Submitted on: Dec 16, 2024
Accepted on: Dec 28, 2024
Published on: Jan 31, 2025
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Sarwat Rasheed, Sidra Javed, Thanyat Rasheed, Shaiza Farman, Elisha Shalim, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.